Compositions and Methods to Enhance the Immune Response
- Detailed Technology Description
- The immune response plays a critical role in protecting humans and animals from infection and the development of tumors. Compositions that increase the immune response (adjuvants) are therefore valuable for improving vaccine efficacy and the control of tumor growth and metastasis. Novel combinations of molecules that are immunostimulatory have been discovered. Certain of these adjuvants have been used to treat a variety of tumor types in mouse models and the results demonstrate dramatic reductions in tumor size and increased survival rates. Additionally, a combination of the molecules has been tested as an adjuvant for an anti-infective vaccine and has produced improved protective effects. This technology is simple, inexpensive, and has broad potential utility for improving existing vaccines against a variety of microbial infections and for improving immunotherapeutic approaches for treating cancer.
- Supplementary Information
- Patent Number: US20090081157A1
Application Number: US2008160303A
Inventor: Kornbluth, Richard Syd | Stone, Geoffrey William
Priority Date: 9 Jan 2006
Priority Number: US20090081157A1
Application Date: 3 Oct 2008
Publication Date: 26 Mar 2009
IPC Current: A61K003820 | A61K003512 | A61K003821 | A61K003900 | A61K0039002 | A61K003902 | A61K003912 | A61P003704 | C12N000500
US Class: 4240852 | 4240854 | 42409371 | 4241841 | 4241981 | 4242041 | 4242341 | 4242691 | 4242771 | 435375
Title: Immunostimulatory Combinations for Vaccine Adjuvants
Usefulness: Immunostimulatory Combinations for Vaccine Adjuvants
Summary: For manufacturing medicament for eliciting an immunotherapeutic responses to an infection or neoplastic diseases; for treating infection or neoplastic diseases; for treating cell proliferation disorder e.g. cancer; for treating antigen (e.g. viral antigen, a bacterial antigen, a parasitic antigen, a protozoal antigen, an abnormal host protein, and a tumor antigen) associated with the infection or neoplastic diseases (claimed).
Novelty: Vaccine comprises tumor necrosis factor receptor superfamily agonists; and Toll-like receptor agonists, Nod-like receptor agonists, retinoic acid inducible gene like helicase agonists, cytokine receptor or purinergic receptor agonist
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Others
-
Additional Technologies by these Inventors
Tech ID/UC Case
20563/2005-252-0
Related Cases
2005-252-0
- *Abstract
-
None
- *Principal Investigator
-
Name: Richard Kornbluth
Department:
Name: Richard Kornbluth
Department:
Name: Geoffrey Stone
Department:
Name: Geoffrey Stone
Department:
- Country/Region
- USA
For more information, please click Here
